The Impact of COVID-19 on the Daily Life and Medical Practice of Otolaryngology Physicians

Elzayat, Saad; Elfarargy, Haitham H.; Mandour, Mahmoud; Mahrous, Ali; El-Deeb, Mohamed E.; Barbara, Maurizio; Elsherief, Hossam

doi:10.1055/s-0042-1745854

Saad Elzayat

Faculty of Medicine, Department of Otorhinolaryngology, Kafrelsheikh University, Egypt

https://orcid.org/0000-0002-9477-2460

Haitham H. Elfarargy

Faculty of Medicine, Department of Otorhinolaryngology, Kafrelsheikh University, Egypt

https://orcid.org/0000-0001-5303-2012

Mahmoud Mandour

Faculty of Medicine, Department of Otolaryngology, Tanta University, Egypt

https://orcid.org/0000-0002-2643-6502

Ali Mahrous

Faculty of Medicine, Department of Otorhinolaryngology, Al-Azhar University, Egypt

https://orcid.org/0000-0003-1084-8753

Mohamed E. El-Deeb Address for correspondence Mohamed El-Deeb, MSc, Department of Otolaryngology, Kafrelsheikh University, El-giesh Street, Kafrelsheikh, Egypt 33155 (e-mail: deeb_van@yahoo.com; mohamed_eldeeb@med.kfs.edu.eg).

Faculty of Medicine, Department of Otorhinolaryngology, Kafrelsheikh University, Egypt

https://orcid.org/0000-0002-6029-8529

Maurizio Barbara

Faculty of Medicine, Department of Otolaryngology, Sapienza Roma University, Italy

https://orcid.org/0000-0003-0740-0384

Hossam Elsherief

Faculty of Medicine, Department of Otolaryngology, Tanta University, Egypt

https://orcid.org/0000-0002-8095-7368

Address for correspondence Mohamed El-Deeb, MSc, Department of Otolaryngology, Kafrelsheikh University, El-giesh Street, Kafrelsheikh, Egypt 33155 (e-mail: deeb_van@yahoo.com; mohamed_eldeeb@med.kfs.edu.eg).

Conflicts of Interests

The authors have no conflict of interests to declare.

Authors’ Contributions

S. Z.: methodology; H. H.: idea formulation and data collection; M. M.: review writing and revision; A. M: reference collection and final revision; M. E.: formal analysis; M. B.: idea formulation and editing final draft; and H. E.: drafting the article or revising it critically for important intellectual content

Please read and answer the following questions carefully	YES	NO	Not sure
1—During the COVID-19 crisis, have you gotten enough infection control education and training?
2—During the COVID-19 crisis, have you gotten enough PPE supply and protection from your institution?
3- During the COVID-19 crisis, has the usage of PPE²2 Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA 2020;323(16):1610–1612. Doi: 10.1001/jama.2020.3227 https://doi.org/10.1001/jama.2020.3227... made ENT³3 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395 (10223):507–513. Doi: 10.1016/S0140-6736(20)30211-7 https://doi.org/10.1016/S0140-6736(20)30... examination difficult and exhausting?
4- During the COVID-19 crisis, have you been afraid of dealing with patients?
5- During COVID-19 , have you been worry about the absence of evidence-based medicine protocols, especially those related to taste and smell sensations lost?
6-Due to COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... , has your medical performance affected by your fear about your family members' health?
7-During COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... , have the telemedicine and online medical consultation been good and enough tools to deal with your patients?
8- Owing to COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... , have your training curve and upgrading been affected?
9-During COVID-19 , have online lectures and webinars been good and enough tools for medical education?
10- Has COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... affected your mood and made you anxious?
11-During the COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... crisis, has quarantine been an excellent opportunity to rest and spend more time with your family?
12-During the COVID-19 crisis, has quarantine been an excellent opportunity to study or finish some research work?
13-Owing to the COVID-19 crisis, have you had an obvious financial problem?
14-After the removal of restrictions, are you afraid of or do you have reservations about returning to your regular clinic duty?
15-Will you continue online medical consultation and telemedicine with your patients?
16-Will you continue online lectures and ENT webinars?
17-Will you continue following COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... progress news and reports?
18-Do you think the approval of an effective vaccine will make you safe during your ENT medical practice?
19- Do you think COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... will have a long-term effect on your ENT career and medical practice?
20-Owing to COVID-19¹1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. [published correction appears in Lancet. 2020 Jan 30;]. Lancet 2020;395 (10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30... , do you think ENT³3 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395 (10223):507–513. Doi: 10.1016/S0140-6736(20)30211-7 https://doi.org/10.1016/S0140-6736(20)30... is a safe specialty?

Item	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20
Q1	0.455	0.797	0.578	0.795	0.626	0.634	0.440	0.440	0.465	0.537	0.829	0.735	0.818	0.633	0.271	0.806	0.889	0.714	0.524
Q2		0.514	0.519	0.460	0.529	0.514	0.434	0.496	0.523	0.498	0.508	0.536	0.431	0.519	0.349	0.433	0.414	0.483	0.692
Q3			0.699	0.867	0.793	0.744	0.665	0.574	0.607	0.791	0.782	0.835	0.867	0.735	0.386	0.873	0.873	0.817	0.654
Q4				0.567	0.819	0.471	0.544	0.754	0.832	0.666	0.606	0.783	0.502	0.511	0.420	0.515	0.502	0.742	0.651
Q5					0.690	0.776	0.609	0.431	0.456	0.753	0.721	0.753	0.926	0.791	0.293	0.906	0.843	0.765	0.561
Q6						0.579	0.661	0.722	0.676	0.823	0.662	0.815	0.618	0.643	0.507	0.633	0.618	0.830	0.758
Q7							0.475	0.358	0.379	0.670	0.597	0.584	0.790	0.929	0.216	0.814	0.749	0.576	0.522
Q8								0.413	0.437	0.555	0.727	0.633	0.631	0.510	0.350	0.626	0.674	0.643	0.580
Q9									0.767	0.614	0.495	0.663	0.382	0.398	0.561	0.392	0.382	0.596	0.569
Q10										0.614	0.506	0.716	0.404	0.407	0.517	0.414	0.404	0.630	0.575
Q11											0.633	0.736	0.687	0.702	0.467	0.755	0.648	0.714	0.650
Q12												0.644	0.754	0.586	0.293	0.781	0.786	0.639	0.561
Q13													0.679	0.596	0.459	0.690	0.679	0.924	0.689
Q14														0.785	0.255	0.939	0.870	0.678	0.507
Q15															0.251	0.788	0.720	0.594	0.557
Q16																0.263	0.258	0.437	0.432
Q17																	0.907	0.695	0.516
Q18																		0.678	0.499
Q19																			0.710

Groups Results
Q N		Residents			Registrars			Consultants			Total			Chi-squared	P-value
Q N		Yes	No	Not Sure	Yes	No	Not sure	Yes	No	Not Sure	Yes	No	Not Sure	Chi-squared	P-value
Q1	N	102	14	9	83	29	13	76	18	31	261	61	53	25.6425	0.00037*
Q1	Per%	81.6	11.2	7.2	66.4	23.2	10.4	60.8	14.4	24.8	69.6	16.27	14.13	25.6425	0.00037*
Q2	N	9	108	8	16	104	5	19	99	7	44	311	20	4.6832	0.32137
Q2	Per%	7.2	86.4	6.4	12.8	83.2	4	15.2	79.2	5.6	11.73	83.93	5.33	4.6832	0.32137
Q3	N	92	23	10	95	22	8	98	17	10	285	62	28	1.4752	0.8310
Q3	Per%	73.6	18.4	8	76	17.6	6.4	78.4	13.6	8	76	16.53	7.47	1.4752	0.8310
Q4	N	118	6	1	113	10	2	116	8	1	347	24	4	1.6095	0.8070
Q4	Per%	94.4	4.8	0.8	90.4	8	1.6	92.8	6.4	0.8	92.53	6.4	1.07	1.6095	0.8070
Q5	N	68	39	18	87	24	14	96	8	21	251	71	53	26.5905	0.000024*
Q5	Per%	54.4	31.2	14.4	69.6	19.2	11.2	76.8	6.4	16.8	66.94	18.93	14.13	26.5905	0.000024*
Q6	N	106	9	10	111	5	9	117	3	5	334	17	24	5.589	0.232014
Q6	Per%	84.8	7.2	8	88.8	4	7.2	93.6	2.4	4	89.07	4.53	6.4	5.589	0.232014
Q7	N	24	74	27	53	48	24	88	25	12	165	147	63	67.8761	< 0.00001*
Q7	Per%	19.2	59.2	21.6	42.6	38.4	9.2	70.4	20	9.6	44	39.2	16.8	67.8761	< 0.00001*
Q8	N	102	5	18	63	48	14	8	107	10	173	160	42	177.9758	< 0.00001*
Q8	Per%	81.6	4	14.4	50.4	38.4	11.2	6.4	85.6	8	46.13	42.67	11.2	177.9758	< 0.00001*
Q9	N	116	6	3	119	2	4	123	1	1	358	9	8	6.6234	0.157181
Q9	Per%	92.8	4.8	2.4	95.2	1.6	3.2	98.4	0.8	0.8	95.47	2.4	2.13	6.6234	0.157181
Q10	N	119	4	2	121	3	1	116	7	2	356	14	5	2.3639	0.669164
Q10	Per%	95.2	3.2	1.6	96.8	2.4	0.8	92.8	5.6	1.6	94.93	3.73	1.33	2.3639	0.669164
Q11	N	83	27	15	109	12	4	114	7	4	306	46	23	30.0835	< 0.00001*
Q11	Per%	66.4	21.6	12	87.2	9.6	3.2	91.2	5.6	3.2	81.6	12.27	6.13	30.0835	< 0.00001*
Q12	N	91	28	6	83	32	10	57	63	5	231	123	21	28.1102	0.000012*
Q12	Per%	72.8	22.4	4.8	66.4	25.6	8	45.6	50.4	4	61.6	32.8	5.6	28.1102	0.000012*
Q13	N	112	4	9	109	11	5	105	8	12	326	23	26	6.2905	0.178476
Q13	Per%	89.6	3.2	7.2	87.2	8.8	4	84	6.4	9.6	86.93	6.13	6.93	6.2905	0.178476
Q14	N	76	29	20	81	14	30	94	9	22	251	52	72	16.8971	0.002024*
Q14	Per%	60.8	23.2	16	64.8	11.2	24	75.2	7.2	17.6	66.93	13.87	19.2	16.8971	0.002024*
Q15	N	30	72	23	58	49	18	93	24	8	181	145	49	64.0188	< 0.00001*
Q15	Per%	24	57.6	18.4	46.4	39.2	14.4	74.4	19.2	6.4	48.27	38.67	13.06	64.0188	< 0.00001*
Q16	N	113	6	6	120	2	3	123	1	1	356	9	10	8.9105	0.063376
Q16	Per%	90.4	4.8	4.8	96	1.6	2.4	98.4	0.8	0.8	94.93	2.4	2.67	8.9105	0.063376
Q17	N	81	16	28	83	20	22	91	15	19	255	51	69	3.3084	0.507596
Q17	Per%	64.8	12.8	22.4	66.4	16	17.6	72.8	12	15.2	68	13.6	18.4	3.3084	0.507596
Q18	N	94	7	24	91	13	21	86	6	33	271	26	78	6.6693	0.15443
Q18	Per%	75.2	5.6	19.2	72.8	10.4	16.8	68.8	4.8	26.4	72.27	6.93	20.8	6.6693	0.15443
Q19	N	109	3	13	113	3	9	107	2	16	329	8	38	2.3676	0.668494
Q19	Per%	87.2	2.4	10.4	90.4	2.4	7.2	85.6	1.6	12.8	87.74	2.13	10.13	2.3676	0.668494
Q20	N	4	108	13	7	109	9	5	112	8	16	329	30	2.354	0.670951
Q20	Per%	3.2	86.4	10.4	5.6	87.2	7.2	4	89.6	6.4	4.26	87.74	8	2.354	0.670951

Q\|N		Answers			Chi-squared	P-value
Q\|N		Yes	No	Not Sure	Chi-squared	P-value
Q1	N	261	61	53	222.208	< 0.0001*
Q1	Per %	69.6	16.27	14.13	222.208	< 0.0001*
Q2	N	44	311	20	417.456	< 0.0001*
Q2	Per%	11.73	83.93	5.33	417.456	< 0.0001*
Q3	N	285	62	28	311.824	< 0.0001*
Q3	Per%	76	16.53	7.47	311.824	< 0.0001*
Q4	N	347	24	4	593.008	< 0.0001*
Q4	Per%	92.53	6.4	1.07	593.008	< 0.0001*
Q5	N	251	71	53	191.808	< 0.0001*
Q5	Per%	66.94	18.93	14.13	191.808	< 0.0001*
Q6	N	334	17	24	524.386	< 0.0001*
Q6	Per%	89.07	4.53	6.4	524.386	< 0.0001*
Q7	N	165	147	63	47.424	< 0.0001*
Q7	Per%	44	39.2	16.8	47.424	< 0.0001*
Q8	N	173	160	42	83.344	< 0.0001*
Q8	Per%	46.13	42.67	11.2	83.344	< 0.0001*
Q9	N	358	9	8	651.656	< 0.0001*
Q9	Per%	95.47	2.4	2.13	651.656	< 0.0001*
Q10	N	356	14	5	640.656	< 0.0001*
Q10	Per%	94.93	3.73	1.33	640.656	< 0.0001*
Q11	N	306	46	23	395.632	< 0.0001*
Q11	Per%	81.6	12.27	6.13	395.632	< 0.0001*
Q12	N	231	123	21	176.448	< 0.0001*
Q12	Per%	61.6	32.8	5.6	176.448	< 0.0001*
Q13	N	326	23	26	484.848	< 0.0001*
Q13	Per%	86.93	6.13	6.93	484.848	< 0.0001*
Q14	N	251	52	72	192.112	< 0.0001*
Q14	Per%	66.93	13.87	19.2	192.112	< 0.0001*
Q15	N	181	145	49	74.496	< 0.0001*
Q15	Per%	48.27	38.67	13.06	74.496	< 0.0001*
Q16	N	356	9	10	640.336	< 0.0001*
Q16	Per%	94.93	2.4	2.67	640.336	< 0.0001*
Q17	N	255	51	69	204.096	< 0.0001*
Q17	Per%	68	13.6	18.4	204.096	< 0.0001*
Q18	N	271	26	78	266.608	< 0.0001*
Q18	Per%	72.27	6.93	20.8	266.608	< 0.0001*
Q19	N	329	8	38	502.992	< 0.0001*
Q19	Per%	87.74	2.13	10.13	502.992	< 0.0001*
Q20	N	16	329	30	500.176	< 0.0001*
Q20	Per%	4.27	87.73	8	500.176	< 0.0001*

[1] Address for correspondence Mohamed El-Deeb, MSc, Department of Otolaryngology, Kafrelsheikh University, El-giesh Street, Kafrelsheikh, Egypt 33155 (e-mail: deeb_van@yahoo.com; mohamed_eldeeb@med.kfs.edu.eg).

Brasil

Brasil

The Impact of COVID-19 on the Daily Life and Medical Practice of Otolaryngology Physicians

Abstract

Introduction

Objective

Methods

Results

Conclusion